Table 3.
Reactive site | Weak contact site | |||||||
---|---|---|---|---|---|---|---|---|
BPTI (3OTJ) | Pro12 | Cys13 | Lys14 | Ala15 | Arg16 | Cys37 | Arg38 | Lys45 |
ΔGbind, Kcal/Mol | −2.1 | −4.8 | −8.1 | −3.3 | −3.2 | −1.8 | −2 | 1.1 |
ΔSASA, Ǻ2 | 33 | 51.6 | 165.2 | 36 | 110.8 | 27.2 | 97.2 | 0 |
BPTI mutant (3BTT) | Pro12 | Cys13 | Thr14 | Ala15 | Arg16 | Cys37 | Arg38 | Lys45 |
ΔGbind, Kcal/Mol | −2.1 | −4,6 | −4.4 | −3.5 | −3.5 | −1.7 | −1.6 | 0.3 |
ΔSASA, Ǻ2 | 37.9 | 55.5 | 101.4 | 36.5 | 118.3 | 28.6 | 94.6 | 0 |
SHPI-1 (3M7Q) | Arg12 | Cys13 | Lys14 | Gly15 | Tyr16 | Cys37 | Gly38 | Glu45 |
ΔGbind, Kcal/Mol | −3.4 | −2.9 | −8.4 | −2.2 | −4.5 | −1.4 | −0.1 | −0.5 |
ΔSASA, Ǻ2 | 143.8 | 52 | 163.6 | 19.9 | 88.7 | 30 | 0.9 | 0 |
InhVJ | Pro12 | Cys13 | Thr14 | Ala15 | Tyr16 | Cys37 | Glu38 | Glu45 |
ΔGbind, Kcal/Mol | −2.1 | −4.4 | −4.7 | −2.6 | −5.9 | −1.1 | −0.2 | −8.4 |
ΔSASA, Ǻ2 | 50.5 | 53 | 106.1 | 30.5 | 102.2 | 37.2 | 0 | 37.9 |